Recent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer Therapy

被引：22
作者：
Lee, Ho-Jae [1 ]
机构：
[1] Gachon Univ, Lee Gil Ya Canc & Diabet Inst, Coll Med, Dept Biochem, Incheon, South Korea
来源：
JOURNAL OF CANCER PREVENTION | 2020年 / 25卷 / 04期
基金：
新加坡国家研究基金会;
关键词：
TGF-beta; Tumor microenvironment; Tumor escape; Antineoplastic agents; Immune checkpoint inhibitors; GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITION; LY2157299; MONOHYDRATE; CANCER; RECEPTOR; EXPRESSION; MEMBRANE; PATHWAY; CELLS; PD-L1;
D O I：
10.15430/JCP.2020.25.4.213
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TGF-beta is a multifunctional cytokine that plays an important role in both physiologic and pathologic processes, including cancer. Importantly, TGF-beta has a dual role in tumorigenesis, acting as a tumor suppressor or a tumor promoter, depending on the stage of tumor development The aberrantly upregulated production of TGF-beta has been strongly implicated in tumor progression, angiogenesis, and metastasis, as well as immune evasion. Therefore, hyperactivated TGF-beta signaling is considered a potential therapeutic target for cancer therapy. Numerous inhibitors of overactivated TGF-beta signaling have been developed, and some of them are currently in clinical trials. This review focuses on the TGF-beta signaling that contributes to tumor progression and immune evasion in the tumor microenvironment and presents recent achievements on TGF-beta signaling inhibition as a single or combined therapeutic approach in cancer therapy.
引用
收藏
页码：213 / 222
页数：10
相关论文
共 85 条
  • [31] Smad7 binds to the adaptors TAB2 and TAB3 to block recruitment of the kinase TAK1 to the adaptor TRAF2
    Hong, Suntaek
    Lim, Seunghwan
    Li, Allen G.
    Lee, Chan
    Lee, Youn Sook
    Lee, Eun-Kyung
    Park, Seok Hee
    Wang, Xiao-Jing
    Kim, Seong-Jin
    [J]. NATURE IMMUNOLOGY, 2007, 8 (05) : 504 - 513
  • [32] Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer
    Ikeda, Masafumi
    Takahashi, Hideaki
    Kondo, Shunsuke
    Lahn, Michael Mauritius Fabio
    Ogasawara, Ken
    Benhadji, Karim A.
    Fujii, Hisaki
    Ueno, Hideki
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (06) : 1169 - 1177
  • [33] Epithelial-mesenchymal transition in cancer development and its clinical significance
    Iwatsuki, Masaaki
    Mimori, Koshi
    Yokobori, Takehiko
    Ishi, Hideshi
    Beppu, Toru
    Nakamori, Shoji
    Baba, Hideo
    Mori, Masaki
    [J]. CANCER SCIENCE, 2010, 101 (02): : 293 - 299
  • [34] Discovery of N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF-β Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent
    Jin, Cheng Hua
    Krishnaiah, Maddeboina
    Sreenu, Domalapally
    Subrahmanyam, Vura B.
    Rao, Kota S.
    Lee, Hwa Jeong
    Park, So-Jung
    Park, Hyun-Ju
    Lee, Kiho
    Sheen, Yhun Yhong
    Kim, Dae-Kee
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (10) : 4213 - 4238
  • [35] Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
    Jochems, Caroline
    Tritsch, Sarah R.
    Pellom, Samuel Troy
    Su, Zhen
    Soon-Shiong, Patrick
    Wong, Hing C.
    Gulley, James L.
    Schlom, Jeffrey
    [J]. ONCOTARGET, 2017, 8 (43) : 75217 - 75231
  • [36] TGF-β signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond syndrome
    Joyce, Cailin E.
    Saadatpour, Assieh
    Ruiz-Gutierrez, Melisa
    Bolukbasi, Ozge Vargel
    Jiang, Lan
    Thomas, Dolly D.
    Young, Sarah
    Hofmann, Inga
    Sieff, Colin A.
    Myers, Kasiani C.
    Whangbo, Jennifer
    Libermann, Towia A.
    Nusbaum, Chad
    Yuan, Guo-Cheng
    Shimamura, Akiko
    Novina, Carl D.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (09) : 3821 - 3826
  • [37] Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors
    Jung, Su Young
    Yug, Ji Seob
    Clarke, Jeffery M.
    Bauer, Todd M.
    Keedy, Vicki L.
    Hwang, Sunjin
    Kim, Seong-Jin
    Chung, Eun Kyoung
    Lee, Jangik I.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (01) : 173 - 183
  • [38] Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study
    Jung, Su Young
    Hwang, Sunjin
    Clarke, Jeffery M.
    Bauer, Todd M.
    Keedy, Vicki L.
    Lee, Hukeun
    Park, Neunggyu
    Kim, Seong-Jin
    Lee, Jangik, I
    [J]. INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 812 - 820
  • [39] A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
    Kelley, R. K.
    Gane, E.
    Assenat, E.
    Siebler, J.
    Galle, P. R.
    Merle, P.
    Hourmand, I. O.
    Cleverly, A.
    Zhao, Y.
    Gueorguieva, I
    Lahn, M.
    Faivre, S.
    Benhadji, K. A.
    Giannelli, G.
    [J]. CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2019, 10
  • [40] Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)
    Lacouture, Mario E.
    Morris, John C.
    Lawrence, Donald P.
    Tan, Antoinette R.
    Olencki, Thomas E.
    Shapiro, Geoffrey I.
    Dezube, Bruce J.
    Berzofsky, Jay A.
    Hsu, Frank J.
    Guitart, Joan
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (04) : 437 - 446
123456789